NanoString Highlights Spatial Biology Research at the 2022 American Association of Cancer Research (AACR) Conference

Rhea-AI Summary

NanoString Technologies (NASDAQ: NSTG) highlighted over 125 studies at the 2022 AACR meeting showcasing the adoption of its platforms in cancer research. With over 110 posters and 15 oral presentations, this marks a record for the company. Key studies utilized the GeoMx Digital Spatial Profiler and CosMx Spatial Molecular Imager, focusing on spatial biology and gene expression. The research includes innovative approaches such as high-plex protein imaging and multi-omic analyses, illustrating the growing importance of spatial profiling in developing cancer therapeutics.

Positive

• Over 125 studies presented at AACR 2022, illustrating strong adoption of NanoString technologies.
• Record number of posters and presentations (110 posters, 15 oral) indicating increased research engagement.
• Highlight on spatial biology technology, including GeoMx DSP and CosMx SMI, emphasizing innovation.
• Research contributions enhance understanding of cancer, potentially leading to better treatment options.

Negative

• None.

Researchers Present Over 125 Studies Enabled by NanoString Platforms, including the new GeoMx Spatial Proteogenomic Workflow and 108-plex Protein Imaging on CosMx

SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the highlights of over 125 studies enabled by NanoString platforms that will be presented at the 2022 meeting of the American Association of Cancer Research (AACR), which will be held April 8-13, 2022.

At AACR 2022, over 110 posters and 15 oral presentations will showcase unique biological insights generated using NanoString Technologies' platforms. This is the largest number of AACR abstracts in a single year for NanoString and demonstrates the increasing adoption of spatial biology in cancer research. These abstracts include at least 36 studies exploring spatial biology using the CosMx™ Spatial Molecular Imager (SMI) and GeoMx® Digital Spatial Profiler (DSP), and 59 studies exploring gene expression using the nCounter® Analysis System.

“NanoString customers continue to make tremendous contributions to our understanding of cancer and the development of cures,” said Brad Gray, president and CEO of NanoString. “We are particularly excited to highlight research studies that leverage our latest product offerings in spatial biology. These include simultaneous detection of RNA and protein on a single slide using GeoMx DSP and 100-plex protein imaging using the CosMx SMI.”

Several studies and presentations that feature the use of NanoString’s spatial biology platforms are highlighted below.

Spotlight Theater, April 12, 10:00-11:00 am CST

NanoString will host a spotlight theater during AACR on April 12 from 10:00-11:00 am CST, featuring Joseph Beechem, Ph.D., senior vice president of R&D and chief scientific officer for NanoString, presenting "Spatial Whole Transcriptome Profiling and Single Cell High-Plex Imaging: Quantum Leaps Forward in Studying Cancer." Arutha Kulasinghe, Ph.D., National Health and Medical Research Council (NHMRC) Research Fellow, Queensland University  of Technology, will present "Spatial genomics in immunotherapy…and COVID-19." And Hargita Kaplan, director of Translational Medicine, Clinical Laboratory Operations, Atreca, Inc., will present "GeoMx DSP WTA Platform TCR Alpha Program Collaboration."

Poster: Multi-omic dissection of immunotherapy response in groups in non-small cell lung cancer
Arutha Kulasinghe, Ph.D., NHMRC Research Fellow, Queensland University of Technology
This study utilized spatial transcriptomics methods, including the GeoMx DSP and multiplex IHC, to define the tumor/stroma compartment specific proteome and transcriptome from a cohort of 2^nd line immunotherapy treated non-small cell lung cancer patients.

Poster: Development of a custom high-plex GeoMx digital spatial profiler breast cancer protein biomarker assay
Christopher Corless, M.D., Ph.D., Oregon Health & Science University
This study's goal was to develop a high-plex assay to simultaneously quantitate 27 established and novel breast cancer (BC)-related immune protein and phosphoprotein biomarkers using the GeoMx DSP. The custom assay performance was compared to standard, immunohistochemistry-based clinical BC biomarker assays (e.g., ER, PR, HER2) across the spectrum of BC subtypes and in multiple laboratories with statistically significant concordance.

Poster: A single-cell, spatial multi-omics atlas and cellular interactome of all major skin cancer types
Quan Ngyuen, Ph.D., University of Queensland
Alongside other multi-omics tools, CosMx SMI was used to generate the first spatial single-cell atlas and cellular interactome of all major skin cancer types (squamous cell carcinoma, basal cell carcinoma, and melanoma). Spatial transcriptomics with CosMx SMI reveals cell-type organization into distinct functional tissue layers and identifies cancer-, patient-, and region-specific differences in cell-cell interaction.

Poster: Subcellular characterization of over 100 proteins in FFPE tumor biopsies with CosMx Spatial Molecular Imager
Zach Lewis, Ph.D., NanoString Technologies
108 proteins were imaged in a breast cancer biopsy using the CosMx Spatial Molecular Imager, representing one of the highest-plex protein imaging studies. CosMx encoding and chemistry enable high-throughput, short-turnaround protein imaging studies on the same instrument as the CosMx single-molecule RNA assay.

Poster: Multi-omic analysis of whole transcriptome and high plex protein assays on a single FFPE slide
Shilah Bonnet, Ph.D., NanoString Technologies NanoString Technologies
The newly developed GeoMx Spatial Proteogenomic workflow enables the co-detection of protein (>100-plex) and RNA (up to 21,000-plex) from a single FFPE slide. The performance of the Proteogenomic workflow has been confirmed on various cell pellets and tissue types.

Oral: AACR NextGen Star, Will Hwang, MD, PhD
April 11, 11:26-11:41 am CST
As an AACR NextGen Star, Will Hwang, M.D., Ph.D., radiation oncologist and research fellow, Massachusetts General Hospital Cancer Center/Harvard Medical School, will present, "Multicellular spatial community featuring a novel neuronal-like malignant phenotype is enriched in pancreatic cancer after neoadjuvant chemotherapy and radiotherapy."

About NanoString Technologies, Inc.

NanoString Technologies is a leading provider of life science tools for discovery and translational research. The company provides three platforms that allow researchers to map the universe of biology. The nCounter® Analysis System, cited in more than 5,300 peer-reviewed publications, offers a way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision. NanoString's GeoMx® Digital Spatial Profiler enables highly multiplexed spatial profiling of RNA and protein targets in various sample types, including FFPE tissue sections, and has been cited in more than 100 peer-reviewed publications. The CosMx™ Spatial Molecular Imager, with commercial availability expected in 2022, enables highly sensitive, high-resolution imaging of hundreds to thousands of RNAs or proteins directly from single cells within morphologically intact whole tissue sections. For more information, visit www.nanostring.com.

NanoString, NanoString Technologies, the NanoString logo, CosMx, GeoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220408005531/en/

Doug Farrell, NanoString

Vice President, Investor Relations & Corporate Communications

dfarrell@nanostring.com

Phone: 206-602-1768

Source: NanoString Technologies, Inc.

FAQ

What is NanoString Technologies presenting at AACR 2022?

NanoString Technologies is presenting over 125 studies, showcasing its platforms' contributions to cancer research at the AACR 2022 meeting.

How many presentations and posters does NanoString have at AACR 2022?

NanoString has a record of over 110 posters and 15 oral presentations at the AACR 2022 meeting.

What technologies does NanoString highlight for cancer research?

NanoString highlights its GeoMx Digital Spatial Profiler and CosMx Spatial Molecular Imager technologies in cancer research.

When is NanoString's spotlight presentation at AACR 2022?

NanoString's spotlight presentation is scheduled for April 12, 2022, from 10:00-11:00 am CST.

What are the implications of the research presented by NanoString?

The research presented by NanoString showcases advancements in spatial biology that could improve cancer understanding and treatment options.